Cargando…

Genome-Wide Association Study of Beta-Blocker Survival Benefit in Black and White Patients with Heart Failure with Reduced Ejection Fraction

In patients with heart failure with reduced ejection fraction (HFrEF), individual responses to beta-blockers vary. Candidate gene pharmacogenetic studies yielded significant but inconsistent results, and they may have missed important associations. Our objective was to use an unbiased genome-wide as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luzum, Jasmine A., Campos-Staffico, Alessandra M., Li, Jia, She, Ruicong, Gui, Hongsheng, Peterson, Edward L., Liu, Bin, Sabbah, Hani N., Donahue, Mark P., Kraus, William E., Williams, L. Keoki, Lanfear, David E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671316/ https://www.ncbi.nlm.nih.gov/pubmed/38002962 http://dx.doi.org/10.3390/genes14112019

Ejemplares similares

Race and Beta‐Blocker Survival Benefit in Patients With Heart Failure: An Investigation of Self‐Reported Race and Proportion of African Genetic Ancestry
por: Luzum, Jasmine A., et al.
Publicado: (2018)

Pharmacogenetic Risk Scores for Perindopril Clinical and Cost Effectiveness in Stable Coronary Artery Disease: When Are We Ready to Implement?
por: Luzum, Jasmine A., et al.
Publicado: (2016)

BNP and Precision Medicine: Tip of an Iceberg
por: Lanfear, David E., et al.
Publicado: (2021)

Genetics of heart rate in heart failure patients (GenHRate)
por: Evans, Kaleigh L., et al.
Publicado: (2019)

278 Eight Pharmacokinetic-related Genetic Variants Were Not Associated with Bleeding from Direct Oral Anticoagulants in Non-valvular Atrial Fibrillation Patients
por: Campos-Staffico, Alessandra M., et al.
Publicado: (2023)

The Use of β-Blockers in Heart Failure with Reduced Ejection Fraction
por: Masarone, Daniele, et al.
Publicado: (2021)

Comparing methods for identifying patients with heart failure using electronic data sources
por: Alqaisi, Fadi, et al.
Publicado: (2009)

Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients
por: Campos-Staffico, Alessandra M., et al.
Publicado: (2022)

Curative effect of β-blocker on various ejection fractions of patients with atrial fibrillation
por: Cao, Wei, et al.
Publicado: (2019)

Resting heart rate in ambulatory heart failure with reduced ejection fraction treated with beta‐blockers
por: Varian, Kenneth D., et al.
Publicado: (2020)

Effects of Beta-Blockers on Heart Failure with Preserved Ejection Fraction: A Meta-Analysis
por: Liu, Feng, et al.
Publicado: (2014)

Mean corpuscular haemoglobin concentration and outcomes in heart failure with preserved ejection fraction
por: Choy, Manting, et al.
Publicado: (2023)

Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis
por: Chatterjee, Saurav, et al.
Publicado: (2013)

Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis
Publicado: (2013)

Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction
por: Tsujimoto, Tetsuro, et al.
Publicado: (2018)

The progress and controversial of the use of beta blockers in patients with heart failure with a preserved ejection fraction
por: Xu, Xizhen, et al.
Publicado: (2019)

Association of Body-Weight Fluctuation With Outcomes in Heart Failure With Preserved Ejection Fraction
por: Li, Yi, et al.
Publicado: (2021)

Myocardial strain to identify benefit from beta‐blockers in patients with heart failure with reduced ejection fraction
por: Park, Chan Soon, et al.
Publicado: (2022)

Effect of aggressive diuresis in acute heart failure with reduced and preserved ejection fraction
por: He, Xin, et al.
Publicado: (2021)

Subclinical Risk Factors for Heart Failure With Preserved and Reduced Ejection Fraction Among Black Adults
por: Zhao, Li, et al.
Publicado: (2022)

Evaluation of β-blocker therapy for long-term outcomes in patients with low ejection fraction after cardiac surgery
por: Fan, Fu-Dong, et al.
Publicado: (2020)

Aggressive beta-blocker titration in stabilized acute heart failure patients with low left ventricular ejection fraction
por: Waranugraha, Yoga, et al.
Publicado: (2021)

β-blocker and 1-year outcomes among patients hospitalized for heart failure with mid-range ejection fraction
por: Wang, Bin, et al.
Publicado: (2021)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Prognostic significance of resting cardiac power to left ventricular mass and E/e’ ratio in heart failure with preserved ejection fraction
por: Chen, Cong, et al.
Publicado: (2022)

A Phase 4, Open-Label, Single-Arm Study Assessing the Efficacy and Safety of Ivabradine in African American Patients with Heart Failure and Reduced Ejection Fraction
por: Lanfear, David E., et al.
Publicado: (2020)

Clinical implication of pulmonary hospitalization in heart failure with preserved ejection fraction: from the TOPCAT
por: Dong, Bin, et al.
Publicado: (2020)

Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis
por: Turgeon, Ricky D., et al.
Publicado: (2019)

Initiation, Continuation, or Withdrawal of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction
por: Gilstrap, Lauren G., et al.
Publicado: (2017)

β‐Blockers and 1‐Year Postdischarge Mortality for Heart Failure and Reduced Ejection Fraction and Slow Discharge Heart Rate
por: Park, Jin Joo, et al.
Publicado: (2019)

Beta-Blockers in Heart Failure with Preserved Ejection Fraction: Could Their Use Be Vindicated as an Acceptable Option in the Future Treatment Guideline?
por: Cho, Jae Yeong
Publicado: (2019)

Use of angiotensin receptor blocker is associated with improved 1 year mortality in heart failure with mid‐range ejection fraction
por: Wang, Bin, et al.
Publicado: (2021)

Guideline Adherence of β-blocker Initiating Dose and its Consequence in Hospitalized Patients With Heart Failure With Reduced Ejection Fraction
por: Zhou, Yiling, et al.
Publicado: (2021)

Combination therapy using tafamidis and neurohormonal blockers for cardiac amyloidosis and a reduced ejection fraction: a case report
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Successful treatment with ivabradine in a β‐blocker‐refractory patient with acute decompensated heart failure with reduced ejection fraction
por: Inoue, Tomoko, et al.
Publicado: (2023)

Clinical Significance of Mean and Pulse Pressure in Patients With Heart Failure With Preserved Ejection Fraction
por: Wei, Fang-Fei, et al.
Publicado: (2021)

Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction
por: Liu, Dan, et al.
Publicado: (2023)

Effects of beta-blocker withdrawal in patients with heart failure with preserved ejection fraction: A protocol for systematic review and meta-analysis
por: Fukuta, Hidekatsu, et al.
Publicado: (2023)

Beta-blocker management in patients admitted for acute heart failure and reduced ejection fraction: a review and expert consensus opinion
por: Schurtz, Guillaume, et al.
Publicado: (2023)

Abnormalities of Mitochondrial Dynamics in the Failing Heart: Normalization Following Long-Term Therapy with Elamipretide
por: Sabbah, Hani N., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gtcm6ttgsmi2dsqp59s25t0b1a